KRAS mutations (often restricted to codon 12) have previously been detected in blood (plasma or serum) samples from patients with pancreatic cancer [14–26], showing large variations in the proportion of detected cases (27% to 93%) probably because of inter-laboratory variability, limited sample sizes, and variable sensitivities of the assays. Here, KRAS is linked to familial pancreatic carcinoma.